Letter | Published:

Hybrid antibodies can target sites for attack by T cells

Naturevolume 314pages628631 (1985) | Download Citation



It would be advantageous in the case of certain diseases to be able to focus a strong T-cell response at a chosen target, for example, in treating cancer or infections that have escaped the normal host response. At present, it seems inconceivable that we could use antigen-specific lines or clones of effector T cells for this purpose because of complications due to the major histocompatibility restriction of T-cell specificity and the problem of rejection of transplanted effector cells. Here we describe a novel technology which combines the power of T lymphocytes in eliminating unwanted cells and causing beneficial inflammatory reactions with the great advantages of monoclonal antibodies (their specificity and availability). We show that heteroconjugates of monoclonal antibodies (referred to hereafter as hybrid antibodies), in which one of the component binding sites is anti-T-cell receptor and the other component binding site is directed against any chosen target antigen, can focus T cells to act at the targeted site. Monoclonal antibodies directed against the T-cell receptor, such as the anti-allotype used here, are mitogenic for resting T cells and can be used to induce effector T cells carrying the T-cell receptor determinant which can then be directed against the target by a hybrid antibody.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Kappler, J., Kubo, R., Haskins, K., White, J. & Marrack, P. Cell 34, 727–737 (1983).

  2. 2

    Meuer, S. C. et al. J. exp. Med. 158, 988–993 (1983).

  3. 3

    Staerz, U. D., Pasternack, M. S., Klein, J. R., Benedetto, J. D. & Bevan, M. J. Proc. natn. Acad. Sci. U.S.A. 81, 1799–1803 (1984).

  4. 4

    Kaye, J., Porcelli, S., Tite, J., Jones, B. & Janeway, C. A. J. exp Med. 158, 836–856 (1983).

  5. 5

    Ertl, H. et al. Proc. natn. Acad. Sci. U.S.A. 79, 7479–7483 (1982).

  6. 6

    Lancki, D. W. & Fitch, F. W. Fedn Proc. 43, 1659 (1984).

  7. 7

    Martz, E. Immun. Today 5, 254–255 (1984).

  8. 8

    Staerz, U. D., Rammensee, H.-G., Benedetto, J. D. & Bevan, M. J. J. Immun. (in the press).

  9. 9

    Haskins, K. et al. J. exp. Med. 160, 452–471 (1984).

  10. 10

    Roehm, N. et al. Cell 38, 577–584 (1984).

  11. 11

    Houston, L. L., Nowinski, R. C. & Bernstein, I. D. J. Immun. 125, 837–843 (1980).

  12. 12

    Staerz, U. D. & Bevan, M. J. ICSU Short Rep. 2 (in the press).

  13. 13

    Bevan, M. J. & Cohn, M. J. Immun. 114, 559–565 (1975).

  14. 14

    Marshak-Rothstein, A. et al. J. Immun. 122, 2491–2497 (1979).

  15. 15

    Ozato, K. & Sachs, D. J. Immun. 126, 317–321 (1981).

  16. 16

    Carlsson, J., Drevin, H. & Axen, R. Biochem. J. 173, 723–737 (1978).

  17. 17

    Jou, Y.-H. & Bankert, R. B. Proc. natn. Acad. Sci. U.S.A. 78, 2493–2496 (1981).

  18. 18

    Chen, S.-S. & Katz, D. H. J. exp. Med. 157, 772–788 (1983).

Download references

Author information


  1. Department of Immunology, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road, La Jolla, California, 92037, USA

    • Uwe D. Staerz
    •  & Michael J. Bevan
  2. Lilly Research Laboratories, 3252 Holiday Court, Suite 101, La Jolla, California, 92037, USA

    • Osami Kanagawa


  1. Search for Uwe D. Staerz in:

  2. Search for Osami Kanagawa in:

  3. Search for Michael J. Bevan in:

About this article

Publication history



Issue Date



Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.